Schwartzberg L - Search Results

1

Getting it right the first time: recent progress in optimizing antiemetic usage.

Schwartzberg L. Schwartzberg L. Support Care Cancer. 2018 Mar;26(Suppl 1):19-27. doi: 10.1007/s00520-018-4116-2. Epub 2018 Mar 19. Support Care Cancer. 2018. PMID: 29556812 Free PMC article.

2

Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation.

Fortner BV, Schwartzberg L, Tauer K, Houts AC, Hackett J, Stolshek BS. Fortner BV, et al. Among authors: schwartzberg l. Support Care Cancer. 2005 Jul;13(7):522-8. doi: 10.1007/s00520-004-0757-4. Epub 2005 Jan 28. Support Care Cancer. 2005. PMID: 15678345

3

Chemotherapy-induced nausea and vomiting: state of the art in 2006.

Schwartzberg L. Schwartzberg L. J Support Oncol. 2006 Feb;4(2 Suppl 1):3-8. J Support Oncol. 2006. PMID: 16499138 Review.

4

Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.

Schwartzberg LS. Schwartzberg LS. J Support Oncol. 2007 Feb;5(2 Suppl 1):5-12. J Support Oncol. 2007. PMID: 17366928 Review.

5

Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?

Schwartzberg LS. Schwartzberg LS. Oncology (Williston Park). 2007 Jul;21(8):946-53; discussion 954, 959, 962 passim. Oncology (Williston Park). 2007. PMID: 17715696 Free article. Review.

6

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study.

Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Schwartzberg LS, et al. Support Care Cancer. 2009 Jan;17(1):91-8. doi: 10.1007/s00520-008-0474-5. Epub 2008 Jul 1. Support Care Cancer. 2009. PMID: 18592276

7

Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.

Schwartzberg LS, Cobb P, Walker MS, Stepanski EJ, Houts AC. Schwartzberg LS, et al. Support Care Cancer. 2009 Aug;17(8):1081-8. doi: 10.1007/s00520-008-0558-2. Epub 2009 Jan 13. Support Care Cancer. 2009. PMID: 19148686

8

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.

Schwartzberg L, Morrow G, Balu S, Craver C, Gayle J, Cox D. Schwartzberg L, et al. Curr Med Res Opin. 2011 Aug;27(8):1613-22. doi: 10.1185/03007995.2011.596201. Epub 2011 Jun 22. Curr Med Res Opin. 2011. PMID: 21696263 Clinical Trial.

9

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Schwartzberg L, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21711119

10

The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.

Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, Pinto A. Schwartzberg LS, et al. Crit Rev Oncol Hematol. 2012 Jul;83(1):59-70. doi: 10.1016/j.critrevonc.2011.09.005. Epub 2012 Feb 7. Crit Rev Oncol Hematol. 2012. PMID: 22321726 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

317 results

Search Page